Patents Assigned to Medarex
  • Transgenic transchromosomal rodents for making human antibodies
    Publication number: 20060026698
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Application
    Filed: September 30, 2005
    Publication date: February 2, 2006
    Applicants: KIRIN BREWERY COMPANY LIMITED, Medarex, Inc.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward Halk
  • Disulfide prodrugs and linkers and stabilizers useful therefor
    Patent number: 6989452
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: January 24, 2006
    Assignee: Medarex, Inc.
    Inventors: Howard P. Ng, Zhihong Li, Danny P. C. McGee, Oliver L. Saunders, Guoxian Wu, David J. King, Valeri Martichonok, Sharon Boyd, Thomas J. Lobl
  • Peptidyl prodrugs and linkers and stabilizers useful therefor
    Publication number: 20060013860
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Application
    Filed: September 12, 2005
    Publication date: January 19, 2006
    Applicant: Medarex, Inc.
    Inventors: Howard Ng, Danny McGee, Guoxian Wu, Jimmie Moore, Zhihong Li, Sanjeev Gangwar, Oliver Saunders, Irina Astafieva
  • Human CTLA-4 antibodies
    Patent number: 6984720
    Abstract: The present invention provides human sequence antibodies against CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: January 10, 2006
    Assignee: Medarex, Inc.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Cytotoxic compounds and conjugates
    Publication number: 20060004081
    Abstract: The present disclosure provides drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-cleavable substrate conjugates, and to methods of treatment using them.
    Type: Application
    Filed: May 19, 2005
    Publication date: January 5, 2006
    Applicant: Medarex, Inc.
    Inventors: Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Zhi-Hong Li, Bilal Sufi
  • Antibodies against Clostridium difficile toxins and uses thereof
    Publication number: 20050287150
    Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
    Type: Application
    Filed: February 4, 2005
    Publication date: December 29, 2005
    Applicants: UNIVERSITY OF MASSACHUSETTS, MEDAREX, INC.
    Inventors: Donna Ambrosino, Gregory Babcock, Teresa Broering, Robert Graziano, Hector Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William Thomas, Hui-Fen Zhang
  • Human monoclonal antibodies against bacillus anthracis protective antigen
    Publication number: 20050287149
    Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: May 21, 2004
    Publication date: December 29, 2005
    Applicant: MEDAREX, INC.
    Inventors: Tibor Keler, Israel Lowy, Laura Vitale, Diann Blanset, Mohan Srinivasan
  • Disulfide prodrugs and linkers and stabilizers useful therefor
    Publication number: 20050272798
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Application
    Filed: June 21, 2005
    Publication date: December 8, 2005
    Applicant: Medarex, Inc.
    Inventors: Howard Ng, Zhihong Li, Danny McGee, Oliver Saunders, Guoxian Wu, David King, Valeri Martichonok, Sharon Boyd, Thomas Lobl
  • CD-10 activated prodrug compounds
    Publication number: 20050267016
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.
    Type: Application
    Filed: December 22, 2004
    Publication date: December 1, 2005
    Applicant: MEDAREX, INC.
    Inventors: Christopher Bebbington, Matthew Nieder, Pina Cardarelli, Sanjeev Gangwar, Lesley Pickford, Chin Pan
  • Human anti-IRTA-5 antibodies
    Publication number: 20050266008
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-5 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-5, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.
    Type: Application
    Filed: March 28, 2005
    Publication date: December 1, 2005
    Applicant: Medarex, Inc.
    Inventors: Robert Graziano, Josephine Cardarelli, Thomas Kempe, Beth Cutter, Mohan Srinivasan
  • Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
    Patent number: 6962981
    Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM?) of the PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM? allows the use of an immunoenzymatic assay for their detection.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: November 8, 2005
    Assignee: Medarex, Inc.
    Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William Thomas Tino
  • Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
    Publication number: 20050208041
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Application
    Filed: April 23, 2004
    Publication date: September 22, 2005
    Applicant: Medarex, Inc.
    Inventors: Josephine Cardarelli, Tseng-hui Chen, David King, Christopher Bebbington, Sarah Pogue, Francis Carr, Stephen Williams
  • Human CTLA-4 antibodies and their uses
    Publication number: 20050201994
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: January 20, 2005
    Publication date: September 15, 2005
    Applicant: Medarex, Inc.
    Inventors: Alan Korman, Edward Halk, Nils Lonberg
  • Expression vector
    Publication number: 20050153394
    Abstract: This invention provides nucleic acids and expression vectors, and host cells transformed with the same, for providing high expression of a desired polypeptide. Also provided are methods of using the expression vectors, nucleic acids, and host cells which have been modified by these compositions, for increasing expression of a gene encoding a desired polypeptide.
    Type: Application
    Filed: September 3, 2004
    Publication date: July 14, 2005
    Applicant: Medarex, Inc.
    Inventor: Amelia Black
  • CD10-activated prodrug compounds
    Patent number: 6897034
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: May 24, 2005
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Matthew H. Nieder, Pina M. Cardarelli, Sanjeev Gangwar, Lesley B. Pickford, Chin Pan
  • Antibody vaccine conjugates and uses therefor
    Publication number: 20040248215
    Abstract: The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (&bgr;hCG) antigen linked to an anti-mannose receptor (MR) antibody.
    Type: Application
    Filed: January 30, 2004
    Publication date: December 9, 2004
    Applicant: MEDAREX, INC.
    Inventors: Tibor Keler, Michael Endres, Lizhen He, Venky Ramakrishna
  • Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
    Publication number: 20040241169
    Abstract: The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
    Type: Application
    Filed: May 27, 2004
    Publication date: December 2, 2004
    Applicant: Medarex, Inc.
    Inventors: Israel Lowy, Geoffrey M. Nichol
  • Human monoclonal antibodies against interleukin 8 (IL-8)
    Publication number: 20040208873
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: December 16, 2003
    Publication date: October 21, 2004
    Applicants: MEDAREX, INC., GENMAB A/S
    Inventors: Jessica Teeling, Paul Parren, Ole Baadsgaard, Debra Hudson, Jorgen Petersen
  • Cells expressing anti-Fc receptor binding components
    Patent number: 6682928
    Abstract: Cells transformed to express on their surface a component which binds to an Fc receptor of an effector cell are disclosed. Also disclosed are expression vectors used to transform the cells. Once transformed, the cells bind to effector cells via the Fc receptor of the effector cell to stimulate an effector cell mediated immune response.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: January 27, 2004
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Robert Graziano, Yashwant M. Deo
  • Human antibodies as diagnostic reagents
    Patent number: 6680209
    Abstract: The invention provides methods of diagnosis using human antibodies. The methods are particularly useful for analyzing human samples containing HAMA or heterophilic antibodies. A human antibody can bind to an analyte in such samples without binding to HAMA or heterophilic antibodies present in the sample. The methods can be effected using a sandwhich format among others.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: January 20, 2004
    Assignees: Biosite, Incorporated, Medarex, Inc.
    Inventors: Joe Buechler, Gunars Valkirs, Jeff Gray, Nils Lonberg